Zobrazeno 11 - 20
of 1 409
pro vyhledávání: ''
Autor:
Motohiro Fujiwara, Junji Yonese, Noboru Numao, Yoshinobu Komai, Iwao Fukui, Shinya Yamamoto, Takeshi Yuasa
Publikováno v:
Targeted Oncology. 15:635-643
Enzalutamide is a novel, non-steroidal anti-androgen that has demonstrated excellent anti-tumor activity for both non-metastatic and metastatic castration-resistant prostate cancer (nmCRPC and mCRPC) patients, and that is being rapidly introduced int
Autor:
Krishnamurthy Ganesh, Suresh K. Rayala, Himavani Pacharla, Roshni Saravanan, Lawrence D'Cruze, Veena Kumari Vuttaradhi, Karthika P Padmavathy, Ganesh Venkatraman, Ravishankar Pitani, D Prathiba, Akkanapally Venu
Publikováno v:
Journal of Molecular Neuroscience. 71:724-733
Malignant astrocytomas presenting in humans of any age group are a challenge to diagnose and treat. Hence, there is a quest for new markers to ascertain their grades and predict disease outcomes. Proline, glutamic acid, and leucine-rich protein 1 (PE
Autor:
Jesper Lagergren, Eivind Ness-Jensen, Hilde Langseth, Shao-Hua Xie, Randi Elin Gislefoss, Fredrik Mattsson
Publikováno v:
International Journal of Cancer
Sex hormonal differences may contribute to the strong male predominance in esophageal adenocarcinoma (EAC), but whether sex hormone levels influence survival in EAC is unstudied. Our study aimed to assess associations between prediagnostic sex hormon
Autor:
Chang-Xing Lyu, Xiao-Long Fu, Wan-Qin Zeng, Qin Zhang, Lan-ting Gao, Wentao Fang, Lei Zhu, Chang-lu Wang
Publikováno v:
Medical Oncology. 39
BackgroundThere are no optimal regimens for advanced thymic epithelial tumors (TETs) when front-line chemotherapy fails. In this study, we aimed to assess the activity of Bevacizumab in combination with routine chemotherapeutic regimen.MethodsPatient
Autor:
Amelia Altavilla, Emanuela Scarpi, Federica Matteucci, Alberto Farolfi, Paola Caroli, Giovanni Paganelli, Cristian Lolli, Giorgia Gurioli, Ugo De Giorgi, Vincenza Conteduca, Giuseppe Schepisi, Nicole Brighi, Giulia Poti
Publikováno v:
Molecular Oncology
Università degli studi di Foggia-IRIS
Molecular Oncology, Vol 16, Iss 2, Pp 538-548 (2022)
Università degli studi di Foggia-IRIS
Molecular Oncology, Vol 16, Iss 2, Pp 538-548 (2022)
Plasma tumour DNA (ptDNA) is a potential early noninvasive biomarker of treatment outcome in metastatic castration‐resistant prostate cancer (mCRPC). Herein, we investigated whether pretreatment ptDNA levels reflect metabolic tumour burden in mCRPC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4282b2f862a524a76a8c0c6e37e4dd5e
https://hdl.handle.net/11392/2472562
https://hdl.handle.net/11392/2472562
Autor:
Tadamichi Denda, Mitsugu Kochi, Masahiro Takeuchi, Takeshi Suto, Masashi Fujii, Takao Takahashi, Dai Manaka, Hiroaki Tanioka, Masahito Kotaka, Akinori Takagane, Tamotsu Sagawa, Akihito Tsuji, Wataru Ichikawa, Hiroki Hara, Hideto Fujita, Ken Shimada, Yuji Negoro, Yoshihiko Segawa, Toshiki Masuishi, Takanori Watanabe, Masato Nakamura
Publikováno v:
British Journal of Cancer
Background Regorafenib or trifluridine/tipiracil as third-line treatment have limited efficacy in metastatic colorectal cancer (mCRC). Methods This Phase 2 trial evaluated the efficacy and safety of irinotecan plus cetuximab rechallenge as third-line
Autor:
Hong Li, Iris Yeong Fung Sheng, Timothy D. Gilligan, Ruby Gupta, Pedro C. Barata, Moshe Chaim Ornstein, Jaleh Fallah, Allison Martin, Jorge A Garcia, Brian I. Rini, Kimberly D Allman
Publikováno v:
Targeted Oncology. 15:477-483
Despite treatment with abiraterone acetate and prednisone (AA/P), most patients with metastatic hormone sensitive prostate cancer (mHSPC) will develop castration-resistant disease (metastatic castration-resistant prostate cancer [mCRPC]). The early i
Autor:
Marek Dudziński, Monika Długosz-Danecka, Małgorzata Wojciechowska, Michal Osowiecki, Elżbieta Iskierka-Jażdżewska, Weronika Piszczek, Jan Maciej Zaucha, Agnieszka Szymczyk, Edyta Subocz, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Beata Kumiega, Krzysztof Giannopoulos, Ryszard Wichary, Marek Hus, Bartosz Pula, Wojciech Jurczak, Tadeusz Robak, Bożena Katarzyna Budziszewska, Janusz Hałka, Wanda Knopinska-Posluszny, Krzysztof Jamroziak, Agnieszka Szeremet, Andrzej Pluta, Daria Zawirska, Paweł Steckiewicz, Jadwiga Hołojda, Ewa Lech-Marańda
Publikováno v:
Anticancer Research. 40:4059-4066
Background/aim To study the long-term clinical efficacy and tolerability of ibrutinib monotherapy in real-world relapsed and refractory chronic lymphocytic leukemia (RR-CLL) patients outside clinical trials. Patients and methods Clinical data of 171
Autor:
Takeshi Yuasa, Kosuke Takemura, Gulanbar Amori, Philip G. Board, Kentaro Inamura, Junji Yonese, Fumitaka Koga
Publikováno v:
Targeted Oncology. 15:347-356
γ-Glutamyltransferase (GGT) is a marker of oxidative stress. Elevated serum GGT is linked to poor survival in various malignancies; however, there are no data on metastatic renal cell carcinoma (mRCC). Additionally, GGT expression in cancer tissues
Autor:
Suneel Mundle, Namphuong Tran, Toshitaka Shin, Kazuhiro Shibayama, Satoshi Fukasawa, Nobuaki Matsubara, Hiroyoshi Suzuki, Noriyuki Ohtake, Sumiko Kitani, Katsuyoshi Hashine, Karim Fizazi
Publikováno v:
Japanese Journal of Clinical Oncology
Background LATITUDE was a randomized, double-blind, international and phase 3 study of abiraterone acetate plus prednisone in patients with high-risk metastatic hormone-naïve prostate cancer. In the first interim analysis of LATITUDE (clinical cutof